Summary The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autologous stem cell rescue, we were interested in the suitability of these second line regimens for mobilising peripheral blood progenitor cells (PBPC). The kinetics of PBPC were studied in 15 patients treated with Dexa-BEAM and granulocyte colony-stimulating factor (G-CSF). Leukocytes started to rise from <0.5 nL 'on day 18 (16)(17)(18)(19)(20)(21)(22) after Dexa-BEAM, and exceeded 10 nL-' on day 20 (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). Peripheral blood CFU-GM peaked on day 21 (19 -28) and declined slowly thereafter; the median leukocyte count was 18.7 nL-' (12.2 -60) on the day of CFU-GM-peak. The maximum number of CFU-GM circulating in peripheral blood was inversely correlated to the duration of leukopenia after Dexa-BEAM. Measurement of CD34 + cells with the monoclonal antibody 8G12-PE (HPCA-2) predicted the number of CFU-GM precisely in both peripheral blood and leukapheresis products (r = 0.90-0.95). Two to six leukapheresis procedures yielded 6.39 x 108 mononuclear cells kg-' (1.82-13.49) containing 44.4 x 104 CFU-GM kg-' (2.2-213.8). Immunophenotypical analysis revealed that the percentage of CD19 + B cells was ver, low in all collection products (less than 1%). Nine patients were autografted with PBPC (15.4-213.8 x 10 CFU-GM kg-1) after myeloablative chemotherapy and experienced rapid and sustained engraftment (Platelets >50 nL-on day + 13 [9 -22]).
High-dose chemotherapy with autologous cell stem rescue is increasingly being used for treatment of relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL). Both autologous bone marrow (BM) and peripheral blood progenitor cells (PBPC) have successfully been employed for restoring haematopoiesis after myeloblative cytotoxic therapy (Philip et al., 1987; Kessinger et al., 1989; Brandwein et al., 1991; Hardingham et al., 1993; Schmitz et al., 1993) . Besides the possibility of less contamination by tumour cells, the major advantage of autologous PBPC transplantation (PBP-CT) over autologous BM transplantation (ABMT) appears to be a more rapid reconstitution of marrow function To et al., 1992) . Since the frequency of PBPC is low in steady-state haematopoiesis (Richman et al., 1976; DeLuca et al., 1992) , mobilisation of progenitor cells into the blood is mandatory before harvesting via leukapheresis becomes practical. Originally, this was achieved by administration of myelosuppressive drugs (cytotoxic mobilisation), resulting in considerably increased PBPC levels during the recovery phase (Richman et al., 1976) . Although highdose cyclophosphamide has been preferentially used for mobilising PBPC Gianni et al., 1989; Bender et al., 1992) , other cytotoxic drugs also are effective (Emminger et al., 1990; Siena et al., 1991; Teshima et al., 1992) . As recombinant human haematopoietic growth factors have become available for clinical application, it has been demonstrated that the PBPC pool can effectively be expanded by granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Diihrsen et al., 1988; Socinski et al., 1988; DeLuca et al., 1992) . Combination with cytotoxic therapy may further improve the yield of CSF-induced PBPC mobilisation (Socinski et al., 1988; Gianni et al., 1989) . chemotherapy in order to debulk tumour and test its sensitivity to cytotoxic therapy. Regimens containing carmustine (BCNU), etoposide, cytarabine, and melphalan, such as the 'mini-BEAM' and the 'Dexa-BEAM' protocols, have shown quick responses in a substantial number of patients and are thus widely used in this situation (Stewart et al., 1991; Chopra et al., 1992; Pfreundschuh et al., 1993) . In order to develop an efficient and economical method for PBPC harvesting in patients with lymphoma, we were interested in the suitability of these salvage regimens for mobilising PBPC. To this end, the kinetics of PBPC were studied in 15 patients who were treated with Dexa-BEAM and G-CSF to determine the optimum timing of PBPC collection.
Patients and methods

Patients
From March 1992 to January 1993, 15 consecutive patients underwent PBPC harvest after Dexa-BEAM for treatment of relapsed or refractory HD (n = 10) or NHL (n = 5). The median age was 37 years (range 24-49). Usually, the first Dexa-BEAM cycle was used for progenitor collection. Most patients were intensively pretreated, having failed 1-4 chemotherapy regimens with or without radiotherapy. Details are given in Table I. Treatment regimens Fully informed consent was obtained before therapy. All patients received G-CSF (5 ,Lg kg-' s.c.) from day 8 (d8) of the Dexa-BEAM protocol until the last day of PBPC collection. The Dexa-BEAM regimen included dexamethasone 3 x 8mg dl-10, BCNU 60mgm 2 d2, etoposide 150-400 mg m-2 d4-7, cytarabine 100 mg m-2 ql2h d4-7, and melphalan 20 mg m2 d3. Total white blood count (WBC), mononuclear cells, CFU-GM, BFU-E, and CD34 + cells were analysed daily during haematopoietic recovery. For patients proceeding to PBPCT, high-dose chemotherapy consisted of cyclophosphamide 6gm-2, etoposide 1000mgm-2 and BCNU 300mgm-2 (CVB) for HD, and BCNU 300mgm-2, etoposide 800mgm-2, cytarabine (1600 mgm-' and melphalan 140mgm-2 (BEAM) for NHL, respectively . Supportive care was performed as described previously (Schmitz et al., 1988) .
Leukapheresis
Leukapheresis was performed with a Fenwal CS3000 blood component separator (Baxter, Munich, Germany) using a double-lumen central-venous catheter. Six to 10 ten liters of blood were processed daily at a flow rate of 30-60 mL min-'. Each leukapheresis product was cryoconserved in liquid nitrogen until the day of transplantation at a cell concentration of 5 x 107mL-1. The patients tolerated the mobilisation and cell separation procedures well.
Preparation of cells for in vitro analysis
To evaluate the percentage of mononuclear cells (MNC), Pappenheim-stained smears from each sample of peripheral blood or the leukapheresis product were used. At least 400 cells per slide were counted. MNC were isolated by density grade centrifugation over Ficoll/Hypaque (Pharmacia, Freiburg, Germany) , washed, and adjusted in supplemented Iscove's modified Dulbecco's medium (IMDM, Life Technologies, Karlsruhe, Germany).
Progenitor cell assays CFU-GM were grown by plating 1 x I05 MNC in 0.3% agar culture medium consisting of 20% FCS and 5% human placenta-conditioned medium in supplemented IMDM. All cultures were done in triplicate. After 14 days of incubation in a humidified atmosphere of 5% CO2 at 37°C, colonies (>40 cells) were counted. For BFU-E, MNC were plated in methylcellulose containing 30% FCS, purified human erythropoietin (Terry Fox Laboratories, Vancouver, Canada) and PHA-leukocyte-conditioned medium as supplements. The further procedure was similar to that of CFU-GM; BFU-E were counted after 14 days. Counting was performed by the same individual throughout the whole study.
Immunophenotyping Preparation of MNC for flow cytometry has been described elsewhere (Dreger et al., 1993b The WBC started to rise from <0.5 nL-' on day 16-22 (median 18) after start of Dexa-BEAM, and exceeded 10.0 nL-' on day 18-28 (median 20). Peripheral blood CFU-GM peaked on day 19-28 (median 21) and declined slowly thereafter. In no instance did the CFU-GM peak occur before the WBC had exceeded 10.0 nL 1; usually, the peak was reached 1 or 2 days after this event ( Figure 1 ). The median WBC on the day of CFU-GM peak was 18.7 nL-' (range 12.2-60). Accordingly, in the last 11 patients PBPC collection was performed after the WBC had increased to more than 10.0 nL-' to avoid unnecessary leukapheresis. CFU-GM maxima also coincided with platelet recovery after Dexa-BEAM (unsustained platelet count > 50 nL-), but this association was less strict than that of CFU-GM and WBC ( Figure 1 ). For further details see Table I .
The peak CFU-GM mL-' blood (0.2-44.1 x 103) was inversely correlated to the number of days to reach a WBC of
Days (day X = first day of WBC > 10 nL-1) Days (day P = first day of pits. >50 nL-1) Figure 1 Kinetics of peripheral blood CFU-GM in relation to WBC a, and platelet recovery b, after Dexa-BEAM (n = 11). The ordinate depicts the medians of the CFU-GM percentages on the corresponding days relative to the individual CFU-GM maxima (= 100% Figure 3) . 
Discussion
The data presented here demonstrate that PBPC can be effectively mobilised by salvage combination chemotherapy (Dexa-BEAM) plus G-CSF. Although it has been recommended that leukapheresis after cytotoxic mobilisation should start as soon as WBC have reached 1 nL-' Siena et al., 1989; Emminger et al., 1990) , and this practice has been adapted for combined cytotoxic/CSFmediated mobilisation (Siena et al., 1991; Teshima et al., 1992) , our experience indicates that the optimum time for harvesting PBPC after Dexa-BEAM + G-CSF is not before the WBC has increased to more than 10 nL-'. If at this time leukapheresis is not possible, sufficient amounts of PBPC can still be collected on at least five subsequent days, provided the G-CSF administration is continued. The absolute numbers of PBPC present in the circulation correlated well with the speed and completeness of WBC recovery, i.e. individuals who exhibited a leukocyte count of 10 nL-' relatively late and never reached 20 nL-' displayed CFU-GM maxima that were 10-100 times lower than those seen in patients with a rapid WBC recovery to >20 nL-'. This observation matches findings obtained in cytotoxic mobilisation (Emminger et al., 1990) . As reported for other mobilisation regimens, CFU-GM maxima were also associated with platelet recovery after CFU-GM mL-' (xlOE3) CD34+cellskg' (x 1OE5) Figure 3 Correlations between CD34 + cells and a, CFU-GM in 57 peripheral blood samples from 12 patients, b, CFU-GM in 25 leukapheresis products from nine patients, and c, BFU-E in 25 leukaphereis products from nine patients. Calculations were done using linear regression analysis, for clarity, plots are given on a logarithmic scale. Dexa-BEAM (Teshima et al., 1992; Emminger et al., 1990) . However, with regard to timing of leukapheresis, the leukocyte count appears to be the more suitable indicator of PBPC expansion because WBC recovery usually becomes evident 2-3 days before the critical value (10 nL-') is reached, whereas the platelet rise often is obscured by platelet transfusions. Moreover, CFU-GM peaks were always preceded by achievement of the critical leukocyte value (10 nL-') but not of the critical platelet value (50 nL-').
While it is well documented that the addition of growth factors strongly increases the efficacy of cytotoxic PBPC mobilisation, investigations indicating the augmentation of CSF-mediated mobilisation by cytotoxic therapy are sparse. Accordingly, in our protocol the importance of Dexa-BEAM for expanding the PBPC pool is not clearly defined. However, the relevance of chemotherapy in this setting is underlined by the fact that we were not able to collect 100 x I04 CFU-GM kg-' or more with 2-3 leukapheresis in a limited number of patients mobilised with G-CSF alone, although previous treatment in general was less intensive than in the cohort treated with Dexa-BEAM + G-CSF (unpublished observations). Larger patient numbers, however, are required to draw definite conclusions on this topic.
The number of CFU-GM necessary for successful trilineage engraftment has been a subject of controversy; recommended minimum CFU-GM doses range from 10 x 104 to 50 x 104 kg-' (Siena et al., 1991; Teshima et al., 1992; To & Juttner, 1987) . This discrepancy may reflect differences in the CFU-GM assays employed, in the agents used for mobilisation, and in the underlying diseases. In our series, rapid and complete engraftment was achieved in each patient who received 10 x 104 CFU-GM kg-' or more; the single patient transplanted with 4.8 x 104 CFU-GM kg-' showed delayed platelet recovery in spite of simultaneous administration of autologous bone marrow. Thus, fewer than The relationship between CD34 and CFU-GM in peripheral blood is well-acknowledged (Bender et al., 1992; Siena et al., 1989; Siena et al., 1991; Brugger et al., 1992; Matsunaga et al., 1993) . However, the correlation found in the present series is much stronger than in most previous studies, which reported correlations between CD34 and CFU-GM mL-' ranging from r = 0 to r = 0.89 (Bender et al., 1992; Siena et al., 1989; Siena et al., 1991; Brugger et al., 1992; Matsunaga et al., 1993; Janssen et al., 1992; Haas et al., 1992) . This may have various reasons: (1) As we and others have observed (Lansdorp et al., 1989) , the affinity and the degree of unspecific binding between different CD34 MoAbs and conjugates varies considerably. A less discriminating CD34 conjugate or indirect CD34 labelling may include unspecific fluorescence and thus affect the CD34/CFU-GM correlation (Brugger et al., 1992; Janssen et al., 1992; Haas et al., 1992 Matsunaga et al., 1993) , but similar to the results obtained by SIENA et al. who used a 8G12-FITC conjugate (Siena et al., 1991) . (2) The fact that colony counting was performed by the same person throughout the whole study may have contributed to the strong CD34 + cell/CFU-GM correlation observed. (3) Finally, the degree of correlation between CFU-GM and CD34 + cells may depend on the method of PBPC mobilisation (Brugger et al., 1992; Janssen et al., 1992) . Altogether, in our study, the CD34 + cell/CFU-GM ratios ranged consistently between 20:1 and 5:1, implying that a leukapheresis yield of >20 x I05 CD34 + cells kg-' reliably predicted for a CFU-GM content of > 10 x 104 kg-'.
When analysing the cellular components of the collection products by immunophenotyping, we found that CD19 + B cells were strongly reduced or undetectable in the PBPC grafts. This phenomenon was much more pronounced in the present series than observed after cytotoxic mobilisation with other agents (Kiesel et al., 1989) , and paralleled findings obtained after BM transplantation (BMT) , where B cells have been reported to be virtually absent from the peripheral blood in the first few weeks after transplant (Ault et al., 1985; Aotsuka et al., 1991; Dreger et al., 1993b) . Thus, Dexa-BEAM appears to produce some kind of 'in vivo B cell depletion' of PBPC grafts. Since PBPCT is used in patients with B cell NHL with BM involvement (Kessinger et al., 1989; Hardingham et al., 1993) , this finding is of particular importance because Dexa-BEAM plus G-CSF might be employed to 'purge' autologous stem cell grafts of such patients.
The NK cell/T cell ratios in the PBPC grafts were in the range expected for normal blood and different from those seen early after BMT, where the NK cell compartment is increased (Ault et al., 1985; Aotsuka et al., 1991) . The PBPC grafts contained a median T cell dose of 1.16 x 10 kg-', or at least three times more T cells than an average BM graft (Mitsuyasu et al., 1986) . Given that T cells play a role in engraftment of allogeneic and autologous BM (Martin, 1990), the high T cell dose contaminating PBPC grafts may contribute to the fast hematopoietic recovery after PBPCT. On the other hand, the high T cell content of PBPC grafts might be a major obstacle for the use of G-CSF-mobilised PBPC in the allogeneic setting (Dreger et al., 1993a) , where T cells are thought to represent the main carriers of graftversus-host reactivity.
Taken together, Dexa-BEAM plus G-CSF can mobilise large amounts of PBPC that are capable of mediating rapid and sustained haematopoietic recovery after high-dose chemotherapy. The progenitor cell content of the leukapheresis produce correlates with the speed of leukocyte recovery after Dexa-BEAM and can rapidly and reliably be assayed by measurement of 8G12-PE (CD34) brightly positive cells.
From a practical point of view, PBPC collection should start immediately after the WBC has exceeded 10.0 nL1 and might be terminated as soon as more than 20 x 105 CD34 + cells are harvested. This schedule (which should apply also to patients treated with the very similar mini-BEAM protocol) will allow asservation of autologous stem cells with a minimum number of leukaphereses, minimum costs, and without causing delay in continuation of salvage chemotherapy.
